Nature communications · 2025
Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Herate Cécile, Ferrier-Rembert Audrey, Relouzat Francis, Gallouët Anne-Sophie, Pascal Quentin, Letscher Hélène, Cavarelli Mariangela, Dereuddre-Bosquet Nathalie, Gros Wesley, Delache Benoit, Langlois Sébastien, Timera Hawa, Jarjaval Fanny, Bossevot Laetitia, Ludot Camille, Brua Catherine, Lechemia Maxence, Ferraris Olivier, Silvestre Nathalie, Le Grand Roger, Tournier Jean-Nicolas
Аннотация
The monkeypox virus (MPXV) outbreak of 2022 caused a human disease with unusual epidemiological and clinical features, notably an increase in human-to-human transmission through sexual contact, predominantly among men who have sex with men (MSM). This evolution underscores the need to reassess prevention and control strategies in the context of a sexually transmitted disease. Here, we show that rectal challenge of male cynomolgus macaques with a 2022 clade IIb MPXV isolate mimics sexual transmission, leading to rectal infection, with systemic and male genital tract dissemination and seminal fluid shedding. Vaccination with modified-vaccinia Ankara (MVA) protected the macaques from subsequent rectal MPXV challenge. However, MVA failed to prevent the disease when administered four days post-exposure to MPXV. These findings have a critical impact on outbreak management and highlight the importance of reevaluating MVA post-exposure prophylaxis protocols.